AADI Bioscience https://validator.w3.org/feed/docs/rss2.html For Healthcare Professionals Contact Us Correlation of <i>nab</i>-sirolimus tumor drug levels and improved tumor suppression in <i>KRAS G12C</i> non-small cell lung cancer xenografts treated with <i>nab</i>-sirolimus in combination with KRAS inhibitors Investors & News Careers Patients Pipeline Our Medicine Company David Dornan, PhD Neil Desai, PhD Dave Lennon, PhD Inactivating <i>TSC1</i> and <i>TSC2</i> alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database Home <i>nab</i> Technology Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database Pipeline Response to Treatment with <i>nab</i>-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas A Phase 2, open-label, single-arm, prospective, multicenter study of <i>nab</i>-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer Phase II Trial of <i>nab</i>-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update Antitumor activity of <i>nab</i>-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts Bryan Ball Phase 2, Multicenter, Open-label Basket Trial of <i>nab</i>-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in <i>TSC1</i> and <i>TSC2</i> (PRECISION1) Caley Castelein, MD Karin Hehenberger, MD, PhD Evaluation of <i>nab</i>-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines <i>nab</i>-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in <i>TSC1</i> and <i>TSC2</i> in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1 Publications and Abstracts Baiteng Zhao, PhD Advanced Malignant PEComa Solid Tumors Harboring Pathogenic Inactivating Alterations in <i>TSC1</i> or <i>TSC2</i> Genes (PRECISION 1) Phase 2, Multicenter Open-label Basket Trial of <i>nab</i>-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in <i>TSC1</i> or <i>TSC2</i> (PRECISION I) Real-world (RW) characterization and frequency of <i>TSC1</i> and/or <i>TSC2</i> alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer Phase 2, Multicenter Open-label Basket Trial of <i>nab</i>-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in <i>TSC1</i> and <i>TSC2</i> (PRECISION 1) Phase 2, Multicenter, Global, Open-Label Basket Trial of<i> nab</i>-Sirolimus for Patients With Inactivating Alterations in <i>TSC1</i> and <i>TSC2</i> (PRECISION 1) Analysis of inactivating alterations in <i>TSC1</i> and <i>TSC2</i> in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in <i>TSC1</i> and <i>TSC2</i> Phase 2 study of <i>nab</i>-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in <i>TSC1</i> and <i>TSC2</i> using the Foundation Medicine genomic database PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in <i>TSC1</i> and <i>TSC2</i> Response to Treatment With <i>nab</i>-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT  A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of <em>nab</em>-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines <i>nab</i>-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study Scott Giacobello, CPA Expanded Access Phase 2, multicenter, open-label basket trial of <em>nab</em>-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in <em>TSC1</em> or <em>TSC2</em> genes (PRECISION I) Analysis of inactivating <i>TSC1</i> and <i>TSC2</i> alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database